Metformin is a first-line therapy for treatment of T2D and has shown in numerous studies to produce anti-cancer effects through inhibition of the mammalian target of rapamycin (mTOR) pathway, which is important in controlling cancer cell proliferations and cell growth [32–34]. This evidence concerns the gene MTOR and type 2 diabetes mellitus.